Likewise, of the 44.6% (80/179) group 1 patients with biochemically recurrent PC, 47.5% (38/80) had positive PSMA PET results (Supplemental Table 1); group 2 consisted of 19 patients enrolled in the 18F-rhPSMA-7.3 clinical trials, for whom FFPE was available. This evidence concerns the gene FOLH1 and pachyonychia congenita.